Publications by authors named "Tomas Stulc"

Claim this Profile
[
[Diabetes management in hospital].
Jan Škrha, Eva Horová, Tomáš Štulc

Vnitr Lek· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis].
Vladimír Soška, David Karásek, Vladimír Bláha, Renata Cífková, Tomáš Freiberger

Vnitr Lek· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Richard Češka, Tomáš Štulc, Lucie Votavová, Lucie Schwarzová, Martina Vaclová

Vnitr Lek· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study.
Tomáš Štulc, Věra Lánská, Michaela Šnejdrlová, Michal Vrablík, Martina Prusíková

Arch Med Sci· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.
Maciej Banach, Tomas Stulc, Ricardo Dent, Peter P Toth

Int J Cardiol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Vladimír Soška, Michal Vrablík, Vladimír Bláha, Renata Cífková, Richard Češka

Vnitr Lek· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin Intolerance: the Clinician's Perspective.
Tomáš Stulc, Richard Ceška, Antonio M Gotto

Curr Atheroscler Rep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Practical approach to statin intolerance].
Tomáš Štulc, Šárka Beránková, Richard Češka

Vnitr Lek· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of cardiovascular disease prevention guidelines into clinical practice: an unmet challenge?
Richard Ceška, Tomáš Štulc

Curr Pharm Des· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins, glycemia, and diabetes mellitus: another point of view.
Tomáš Stulc, Richard Ceška

Curr Atheroscler Rep· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivabradine, coronary heart disease, and heart failure: time for reappraisal.
Tomáš Stulc, Richard Ceška

Curr Atheroscler Rep· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivabradine in stable coronary artery disease.
Tomas Stulc, Richard Ceska

N Engl J Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Prevention of cardiovascular diseases in clinical practice: is it possible to achieve improvement?].
Tomáš Štulc, Michaela Šnejdrlová, Richard Češka

Vnitr Lek· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Tomas Stulc, Richard Ceska, Iuri Marinov, Jan Skrha

Neuro Endocrinol Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?
Tomas Stulc, Aleksi Sedo

Diabetes Res Clin Pract· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels.
Jaroslav A Hubacek, Wu-Wei Wang, Zdena Skodová, Vera Adámková, Michal Vráblík, Tomás Stulc

Clin Chem Lab Med· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
Tomas Stulc, Richard Ceska

Med Hypotheses· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
Tomas Stulc, Richard Ceska

Med Sci Monit· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Michal Vrablík, Milada Dobiásová, Tomás Stulc, Zdislava Kasalová, Radka Dolezalová

Neuro Endocrinol Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Tomas Stulc, Richard Ceska

Med Hypotheses· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes.
Tomas Stulc, Zdislava Kasalova, Hana Krejci, Radka Dolezalova, Richard Ceska

Atherosclerosis· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeatability of noninvasive surrogates of endothelial function.
Jan Malik, Dan Wichterle, Tomas Haas, Vojtech Melenovsky, Jan Simek, Tomas Stulc

Am J Cardiol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Jan Skrha, Tomás Stulc, Jirina Hilgertová, Hana Weiserová, Jan Kvasnicka

Eur J Pharmacol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Tomás Stulc, Ivan Malbohan, Jan Malík, Lenka Fialová, Jirina Soukupová

Am Heart J· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Vojtech Melenovsky, Tomas Stulc, Viktor Kozich, Barbora Grauova, Jakub Krijt

Am Heart J· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis